Cereius Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Cereius General Information
Description
Developer of radiotherapy techniques intended to treat solid tumor brain metastasis. The company's techniques increase the uptake and retention of radionuclides in the target tumor while minimizing uptake by normal tissues, significantly enhancing the therapeutic index and diagnostic contrast of targeting agents, enabling medical practitioners to treat the brain metastasis of patients and improve their chances of survival.
Contact Information
Website
www.cereius.ioCorporate Office
- 701 West Main Street
- Suite 200
- Durham, NC 27701
- United States
Corporate Office
- 701 West Main Street
- Suite 200
- Durham, NC 27701
- United States
Cereius Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 22-Jun-2023 | Completed | Pre-Clinical Trials | |||
| 2. Debt - General | 12-Feb-2020 | Completed | Pre-Clinical Trials | |||
| 1. Early Stage VC (Series A) | 25-Jul-2018 | $6.75M | $6.75M | Completed | Pre-Clinical Trials |
Cereius Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A3 | ||||||||
| Series A2 | ||||||||
| Series A1 | 916,190 | $0.000100 | 6% | $0.58 | $0.58 | 1x | $0.58 | 8.95% |
Cereius Patents
Cereius Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023276697-A1 | Her2-binding agents and uses thereof | Pending | 23-May-2022 | ||
| EP-4529540-A1 | Her2-binding agents and uses thereof | Pending | 23-May-2022 | ||
| JP-2025522306-A | Her2-binding agents and uses thereof | Pending | 23-May-2022 | ||
| US-20260184811-A1 | Her2-binding agents and uses thereof | Pending | 23-May-2022 | ||
| WO-2023230488-A1 | Her2-binding agents and uses thereof | Inactive | 23-May-2022 | C07K16/32 |
Cereius Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Mission BioCapital | Venture Capital | Minority |
Cereius FAQs
-
When was Cereius founded?
Cereius was founded in 2017.
-
Where is Cereius headquartered?
Cereius is headquartered in Durham, NC.
-
What industry is Cereius in?
Cereius’s primary industry is Drug Discovery.
-
Is Cereius a private or public company?
Cereius is a Private company.
-
What is Cereius’s current revenue?
The current revenue for Cereius is .
-
How much funding has Cereius raised over time?
Cereius has raised $7.25M.
-
Who are Cereius’s investors?
Mission BioCapital has invested in Cereius.
-
When was Cereius acquired?
Cereius was acquired on 22-Jun-2023.
-
Who acquired Cereius?
Cereius was acquired by Solve Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process